Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients

Abstract

Our study confirms bIgE as a reliable biomarker predicting response to omalizumab in CSU, while it does not support the usefulness of bd-dimer unlike previous findings. CSU duration before omalizumab and baseline UAS7 may be clinical markers of relapse risk.